雷贝拉唑改善消化性溃疡症状情况及其安全性研究

The symptomatic improvement and safety of rabeprazole on peptic ulcer

目的观察雷贝拉唑对消化性溃疡相关症状的改善程度及其安全性。方法在浙江省13家医院进行多中心、开放试验。观察对象:经胃镜诊断为消化性溃疡,有上腹痛、反酸和上腹烧灼感等症状的患者。服用雷贝拉唑片(波利特)10mg,每晨服一次,共5d;记录用药前1天及用药后第1、2、5天的症状并评分,同时记录出现的不良反应。结果本试验共入选消化性溃疡患者1159例。第1、2、5天患者总体症状缓解率分别为67.5%、98.3%、99.7%;而总体症状消失率分别为23.3%、51.8%、83.6%。第2、5天的缓解率及消失率分别与第1天相比差异均有统计学意义(均P<0.01)。结论雷贝拉唑能快速有效的缓解消化性溃疡患者的症状,安全性好。

Objective To observe the symptomatic improvement and safety of rabeprazole in treatment of patients with peptic ulcer. Methods One thousand one hundred and fifty nine patients with peptic ulcer identified by gastroscopy were recruited from 13 hospitals in this multi-center open clinical trial. All patients were given rabeprazole 10mg/d for 5 days, and the symptoms of epigastric pain, acid regurgitation and heart burn as well as side-effects were recorded daily during the therapy. Results The alleviating rate of all symptoms was 67.5%,98.3% and 99.7% in the lst,2nd and 5th day, while the dissolving rate of symptoms was 23.3%, 51.8% and 83.6%, respectively, Alleviating rate and dissolving rate in the 2nd and 5th day were much higher than the 1st day （P〈0.01）, Conclusion Rabeprazole is highly effective and safe in relieving the symptom of peptic ulcer,